Related Experiment Video
Updated: Feb 24, 2026

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
Published on: November 15, 2024
Glutathione S-transferase Mu 3 Mitigates Alcohol-induced Hepatic Lipid Dysregulation via PYGM Suppression
Ran Xia1, Lu Wang1, Chen-Chen Zhao1
1Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Abstract:
Hepatic steatosis is the most prevalent and earliest pathological change in alcoholic hepatitis and represents a critical initiating event in alcohol-associated liver disease (ALD). However, the molecular mechanisms underlying alcohol-induced hepatic lipid dysregulation remain incompletely understood. Here, we investigated the role of glutathione S-transferase Mu 3 (GSTM3) in hepatic lipid metabolism during ALD and explored its underlying mechanism. Using an ALD mouse model and ethanol (EtOH)-treated AML-12 cells, we examined the functional interaction between GSTM3 and glycogen phosphorylase, muscle associated (PYGM), which was identified as a downstream candidate through RNA sequencing (RNA-seq). We found that GSTM3 expression was markedly upregulated in primary hepatocytes isolated from ALD mice and EtOH-treated AML-12 cells, whereas GSTM3 deficiency significantly exacerbated hepatic lipid accumulation both in vivo and in vitro. Mechanistically, GSTM3 knockdown resulted in increased PYGM expression at both the mRNA and protein levels. Importantly, rescue experiments revealed that concomitant silencing of PYGM partially alleviated the enhanced lipid accumulation induced by GSTM3 deficiency, indicating that PYGM contributes to the steatotic phenotype downstream of GSTM3 loss. Collectively, these findings identify GSTM3 as a critical protective regulator of alcohol-induced hepatic steatosis and reveal a previously unrecognized GSTM3-PYGM axis that modulates lipid metabolism in ALD, suggesting GSTM3 as a potential therapeutic target for the treatment of ALD.
Related Concept Videos
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

